Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR 2.652
-0.025 (-0.93%)
Nov 12, 2026, 9:24 AM CET
Valneva SE Employees
Valneva SE had 620 employees as of June 30, 2026. That makes Valneva SE the 18,404th largest employer in the world and 251st in France.
Employees
620
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€230,545
Profits / Employee
€254,274
Market Cap
504.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 620 | - | - |
| Dec 31, 2025 | 674 | -39 | -5.47% |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Genfit | 180 |
| DBV Technologies | 179 |
| Transgene | 152 |
| MedinCell | 141 |
| Innate Pharma | 120 |
| Nanobiotix | 98 |
| Inventiva | 87 |
Valneva SE News
- 2 days ago - Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ - Nasdaq
- 2 days ago - Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 3 days ago - Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2 - Nasdaq
- 3 days ago - Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 7 days ago - Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 - GlobeNewsWire
- 4 weeks ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire
- 5 weeks ago - UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide - Nasdaq
- 5 weeks ago - Valneva announces Ixchiq marketing authorization revoked by UK MHRA - TheFly